PATENT CLAIM ANALYSIS

Application Number: 16242902
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-07
Patent Classification: ["514", "338000"]

Abstract:
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.

Claim (Index 12):
The pharmaceutical composition of  claim 10 , wherein said pharmaceutical composition is in an oral form.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 99.0
- Lexical Diversity: 1.06667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15695118', '15695129', '15695107', '13478534', '13478568']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8043270151603195
- 35 USC 102 Novelty (BERT): 0.6000374028988097
- Combined Prediction Score: 0.7838980539341686
- Mean Citation Score: 455.527282
- Max Citation Score: 492.78116
- Similarity Product: 488.0614834174393

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test